Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 223

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 223
---
 are referred to as the “February 2024 PIPE Financing.”

April 2024 PIPE Financing

On April 1, 2024, the Company
consummated a private placement of 626 shares of the Series B Preferred Stock, pursuant to the Securities Purchase Agreement, dated March
28, 2024, by and among the Company and certain accredited investors, for aggregate cash proceeds to the Company of approximately $0.5
million (the “April 2024 PIPE Financing”).

September 2024 PIPE Financing

In September 2024, the Company
consummated a private placement of 2,853 shares of the Series C Preferred Stock with common warrants to purchase 81,752 shares of Common
Stock (giving retroactive effect to the Reverse Stock Split) pursuant to the Securities Purchase Agreement, dated September 25, 2024,
by and among certain accredited investors for aggregate cash proceeds to the Company of approximately $1.25 million.

Investigational New Drug Application Submission

On June 28, 2024, the Company
submitted an Investigational New Drug Application (“IND”) for its product candidate, CER-1236, to FDA. On July 26, 2024,
the Company was informed by the FDA that it has placed a clinical hold on the IND. The FDA indicated that the clinical hold has been
placed as a result of insufficient data provided with regard to two issues within pharmacology and toxicology of CER-1236. The FDA indicated
that, within 30 calendar days, it would provide a detailed official hold letter and requested that the Company hold its response until
after receipt of such letter (the “Hold Letter”).

The Company received the
Hold Letter on July 26, 2024 and submitted a complete response letter to the FDA on October 21, 2024 in which the Company requested a
meeting to address the FDA’s questions.

On November 15, 2024, the
Company received notice from the FDA that the IND for CER-1236 was cleared. The Company continues to believe that it will be able to
initiate the planned clinical trial by early 2025.

Nasdaq Notices of Non-compliance

On July 19, 2024, the Company
received a letter (the “Bid Price Requirement Letter”) from the staff at The Nasdaq Global Market (“Nasdaq”)
notifying the Company that, for the 30 consecutive trading days prior to the date of